Previous 10 | Next 10 |
5 Top Biotech Stocks To Watch Today The stock market offers plenty of opportunities for investors. Some industries would still catch the attention of investors regardless of the broader market sentiment. A prime example would be biotech stocks . Now, why is that so? For starters...
Antares Pharma (NASDAQ:ATRS) was downgraded by five firms — Truist, Ladenburg, Raymond James, Piper Sandler and H.C. Wainwright — after Halozyme Therapeutics (HALO) said on April 13 that it was acquiring Antares Pharma (ATRS) for ~$960M. Truist analyst Gregory Fraser downgr...
Stocks rebounded from recent weakness on Wednesday, as bargain hunting among beaten-down growth stocks pushed the major averages higher. The Nasdaq led the advance, climbing about 2% on the day. Travel stocks contributed to the upswing. An upbeat earnings report from Delta Air Lines raised ho...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Late-stage biopharmaceutical company Sierra Oncology (NASDAQ: SRRA ) is up big today on news that GlaxoSmithKline (NYSE: GSK ) will purchase the business . Indeed, SRRA stock is up a massive 38% so far today on...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Antares Pharma (NASDAQ: ATRS ) stock is rocketing higher on Wednesday after the pharmaceutical company reached an acquisition agreement with Halozyme Therapeutics (NASDAQ: HALO ). Source: Shutterstock Th...
Shares of the drug delivery specialist Antares Pharma (NASDAQ: ATRS) jumped by as much as 49.2% in premarket action Wednesday morning. The company's stock is bolting higher in response to a $960 million definitive merger agreement with Halozyme (NASDAQ: HALO) . Per the t...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Join me today as we break down all the news behind the biggest pre-market stock movers for Wednesday! Source: f11photo/Shutterstock.com Moving stocks this morning are earnings reports, acquisition deals, insider buy...
Halozyme to Acquire Antares Pharma to Create a Specialty Product and Drug Delivery Leader PR Newswire Transaction Expected to be Immediately Accretive to Revenue and Non-GAAP Earnings in 2022 with Multiple Drivers to Accelerate Financial Growth Through 2027 and Bey...
Halozyme Therapeutics (NASDAQ:HALO) is nearing a deal to acquire Antares Pharma (NASDAQ:ATRS) for ~960M, The Wall Street Journal reported citing people familiar with the matter. The deal could be announced today, April 13. Shares of Antares rose +44.39% to $5.40 pre-market Apri...
Genmab (GMAB) said an arbitral tribunal has ruled in favor of Johnson & Johnson's (NYSE:JNJ) Janssen Biotech in both matters related to royalty payments under their license agreement related to cancer drug daratumumab. On the first issue, the tribunal determined by maj...
News, Short Squeeze, Breakout and More Instantly...
Halozyme Therapeutics Inc. Company Name:
HALO Stock Symbol:
NASDAQ Market:
Halozyme Therapeutics Inc. Website:
Halozyme to Report Second Quarter 2024 Financial and Operating Results PR Newswire SAN DIEGO , July 23, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced it will release its second quarter 2024 financial and operating re...
2024-07-22 03:26:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...